Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11759504 PTH compounds with low peak-to-trough ratios

Patent 11759504 was granted and assigned to Ascendis Pharma on September, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
Ascendis Pharma
Ascendis Pharma
Date Filed
September 28, 2017
Date of Patent
September 19, 2023
Patent Applicant
Ascendis Pharma
Ascendis Pharma
Patent Application Number
16337955
Patent Citations
‌
US Patent 8865220 Method for controlled release of parathyroid hormone from encapsulated poly(lactic-glycolic)acid microspheres
‌
US Patent 8946405 Controlled release from solid supports
‌
US Patent 8906847 Prodrug comprising a drug linker conjugate
‌
US Patent 7585837 Reversible pegylated drugs
‌
US Patent 7820179 Pegylated PTH as PTH receptor modulators and uses thereof
‌
US Patent 8101729 Pegylated amino acid derivatives and the process to synthesize the same
‌
US Patent 8618124 Heterobifunctional polymeric bioconjugates
‌
US Patent 8754190 Controlled release from macromolecular conjugates
Patent Inventor Names
Thomas Wegge
Lars Holten-Andersen
Guillaume Maitro
Kennett Sprogøe
David Brian Karpf
Joachim Zettler
Mathias Krusch
Felix Cleemann
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11759504
Patent Primary Examiner
‌
Christina Bradley

Find more entities like US Patent 11759504 PTH compounds with low peak-to-trough ratios

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo